Episode summary
Supercharging A New FDA: Marty Makary on Science, Power & Patients
All-In Podcast
· · Hosts: David Friedberg, Chamath Palihapitiya, Jason Calacanis, David Sacks · Guests: Marty Makary
Summary
Marty Makary argues that the FDA is trying to move faster without abandoning safety, and that the agency has already pushed through 42 major reforms in 10 months. He says the core goal is to replace “status quo” timelines with clearer, more transparent decisions, including public rejection letters, priority reviews, and new pilot programs meant to get decisions out in weeks instead of years.
A major theme is U.S. competitiveness with China and other countries in biotech. Makary says the U.S. is losing ground because of red tape in IRBs, hospital contracting, and FDA workflows, and he wants more centralized review, more use of AI, and fewer animal-testing requirements. He also argues that continuous trials, Bayesian statistics, and real-time postmarket surveillance could speed approvals while catching safety signals earlier.
The conversation also covered food and drugs as public-health levers. Makary says the food pyramid was distorted by nutrition dogma and industry influence, and that the new guidance emphasizes protein and real food. On GLP-1s, he says obesity is evidence that the food system has failed, while on pricing he says the administration is pushing most-favored-nation pricing and faster biologics pathways to reduce the cost of drugs in the U.S.
Key takeaways
- Makary says the FDA has announced 42 major reforms in 10 months and is trying to make review decisions more transparent and faster.
- He argues the U.S. is behind China in biotech and needs centralized IRBs, streamlined contracts, and AI-assisted review to stay competitive.
- Makary says moving from two pivotal trials to one could save companies $100 million to $300 million and shorten time to market.
- He says the FDA is pushing continuous trials and Bayesian statistics so safety and efficacy can be tracked in real time.
- Makary argues the old food pyramid was wrong, and that new guidance should emphasize protein, real food, and lower refined carbohydrates.
- He says drug prices can fall through most-favored-nation pricing and faster biologics approvals.
How the episode opens
Marty McCary, commissioner of the FDA. Welcome to San Francisco. — Great to be here, Dave. Good to be with you. — Yeah, thanks. It's JP Morgan Healthcare Conference this week in San Francisco. Considered, I think, probably the biggest most important biotech conference globally. Very important week. So, you're visiting this week for the conference.
Yeah. 120,000 people, great conversations. You hear from everybody. Just not enough time to meet with everybody you want to meet with, but it's a great time. — Well, thanks for sitting down with me. You and I have gotten to know each other a little bit over the last year or so
And I'm really excited uh to hear a little bit about how things are going. It's been almost a year since you've been in the role. I think maybe for our audience you could share a little bit about how you got this role.
How did you get involved with this administration? How did you get connected with them? And maybe we can go all the way back to your very outspoken views uh during the COVID pandemic and maybe how that brought attention to you and your philosophies that that drove this role.
Yeah. So my um interest in academia, I um went to graduate school for public health and served on the faculty of the Johns Hopkins School of Public Health as I also had a clinical practice in GI and cancer surgery at Johns Hopkins. And my interest was always in the root causes of our healthcare system problems from quality, transparency, and price.
And in the work on price, uh, I led sort of a national effort to try to get more price transparency of hospital prices. I wrote a book on it that did very well.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- fda reforms
- drug approval timelines
- obesity and glp-1s
- vaccine strategy
- drug pricing and healthcare ai
Watch the episode
Watch “Supercharging A New FDA: Marty Makary on Science, Power & Patients” on YouTube
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from All-In Podcast
-
Jensen OUT as Nvidia CEO: "Spy" Scandal, Export Restrictions, Market Impact -
Freedom vs. Safety: Axon CEO Rick Smith on the Future of Policing -
Midterm Blood Bath, $4T AI Sell Off, Data Center Freeze, What’s Next for Trump -
All-In Podcast REACTS to Democrat Sweep! -
Anthropic S-1 Shocker, Greatest Business Ever? Google’s $500B Wipeout, Midterm Predictions -
WHOOP CEO, Will Ahmed: 50B Hours of Health Data, a 4 Million Member Data Moat, & the FDA Fight
All-In Podcast, this episode and its artwork belong to All-In Podcast, LLC. Octagon is not affiliated with the show; this page is an independent summary.
